Dr. Tabernero on Molecular Characterization in GI Cancer

Video

Josep Tabernero, MD, PhD, from the Vall d'Hebron University Hospital, believes that in order to treat patients with gastrointestinal cancers more effectively, researchers must focus on the molecular classification of particular subpopulations.

Josep Tabernero, MD, PhD, of Vall d’Hebron University Hospital, Barcelona, believes that in order to treat patients with gastrointestinal cancers more effectively, researchers must focus on the molecular classification of particular subpopulations.

Defining unique subtypes within broad tumor classes will help researchers discover key underlying molecular drivers, Tabernero states. Once discovered, these molecular classifications will aid the development of focused targeted agents for patients with advanced malignancies.

Initially, Tabernero believes, the application of these unique molecular characterizations, gene profiles, and expressed proteins will apply mostly to advanced disease. However, they will be translated into earlier stages through the introduction of new treatment options. These targeted treatment approaches, Tabernero states, will result in better treatment outcomes than conventional therapies.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,